Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development
Oragenics files 2025 annual report, highlights ONP-002 progress for concussion treatment. Company achieved NYSE compliance, $16.5M capital raise, and U.S. manufacturing
2026/03/17